Handelsbanken Fonder AB Has $36.29 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Handelsbanken Fonder AB decreased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 56.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 490,165 shares of the medical research company's stock after selling 643,147 shares during the quarter. Handelsbanken Fonder AB owned 0.08% of Edwards Lifesciences worth $36,287,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. State Street Corp increased its position in shares of Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company's stock valued at $1,733,270,000 after purchasing an additional 256,538 shares during the period. Geode Capital Management LLC raised its stake in shares of Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company's stock worth $889,050,000 after buying an additional 284,918 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company's stock valued at $599,078,000 after buying an additional 806,705 shares during the period. Finally, Jennison Associates LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at about $555,939,000. Institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

EW has been the topic of several research reports. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group increased their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of "Hold" and an average price target of $79.95.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the business's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Down 2.0 %

EW traded down $1.46 on Friday, reaching $73.25. 2,843,619 shares of the company traded hands, compared to its average volume of 4,417,774. The company has a market cap of $43.20 billion, a price-to-earnings ratio of 10.51, a PEG ratio of 4.82 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock's 50 day moving average price is $72.86 and its 200-day moving average price is $69.86. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.